Dermatofibrosarcoma protuberans: A review of the literature

Dermatologic Surgery

Volumn 38, Issue 4, 2012, Pages 537-551

  Bogucki, Benjamin ^a   Neuhaus, Isaac ^b   Hurst, Eva A ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ANEMIA; CANCER INCIDENCE; CANCER RECURRENCE; CANCER SURGERY; CLINICAL FEATURE; DERMATOFIBROSARCOMA PROTUBERANS; DRUG DOSE REDUCTION; EDEMA; GASTROINTESTINAL DISEASE; HISTOPATHOLOGY; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; LIVER TOXICITY; METASTASIS; MOHS MICROGRAPHIC SURGERY; MOLECULAR BIOLOGY; MYALGIA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT PLANNING; TREATMENT RESPONSE; WIDE EXCISION;

DERMATOFIBROSARCOMA; HUMANS;

EID: 84859443922     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2011.02292.x     Document Type: Review

References (119)

1. Taylor R. Sarcomatous tumors resembling in some respects keloids. Arch Dermatol 1890;8:384-7.
2. Hoffman E. Ueber alas knollentribende fibrosarkam derhaut (dermatofibrosarcoma protuberans). Dermatol Z 1925;43:1-28.
3. Chuang T, Su W, Muller S. Incidence of cutaneous T cell lymphoma and other rare skin cancers in a defined population. J Am Acad Dermatol 1990;23:54-6.
4. Bendix-Hansen K, Myhre-Jensen D, Haae S. Dermatofibrosarcoma protuberans: a clinico-pathological study of nineteen cases and review of world literature. Scand J Plast Reconstr Surg Hand Surg 1983;17:247-52.
5. Criscione V, Weinstock M. Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol 2007;56:968-73. (Pubitemid 46720204)
6. Bowne W, Antonescu C, Leung D, Katz S. et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer 2000;88:2711-20. (Pubitemid 30417931)
7. Fiore M, Miceli R, Mussi C, Lo Vullo S. et al. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. J Clin Oncol 2005;23:7669-75. (Pubitemid 46291832)
8. Love W, Keller S, Tamburro J, Honda K, et al. Surgical management of congenital dermatofibrosarcoma protuberans. J Am Acad Dermatol 2009;61:1014-23.
9. Gloster H. Dermatofibrosarcoma protuberans. J Am Acad Dermatol 1996;35:355-74.
10. Garg S, Subbuswamy S, Alabi J, Lawrie J. Dermatofibrosarcoma protuberans Northern Algeria: a clinical pathologic review of 17 cases. Clin Oncol 1978;4:113-22. (Pubitemid 8373666)
11. Halder R, Bang K. Skin cancer in blacks in the United States. Dermatol Clin 1986;6:397-405.
12. Lindner N, Scarborough M, Powell G, Spanier S, et al. Revision surgery in dermatofibrosarcoma protuberans of the trunk and extremities. Eur J Surg Oncol 1999;25:392-7. (Pubitemid 29364226)
13. Taylor H, Helwig E. Dermatofibrosarcoma protuberans: a study of 115 cases. Cancer 1962;15:717-25.
14. Pack G, Tabah E. Dermatofibrosarcoma protuberans: a report of thirty-nine cases. Arch Surg 1951;62:391-411.
15. Burkhardt B, Soule E, Winkelmann R, Ivins J. Dermatofibrosarcoma protuberans: study of fifty-six cases. Am J Surg 1966;111:638-44.
16. McPeak C, Cruz T, Nicastri A. Dermatofibrosarcoma protuberans: an analysis of 86 cases-five with metastases. Ann Surg 1967;166:803-16.
17. Doufekas K, Duncan T, Williamson K, Varma S, et al. Mohs micrographic surgery for dermatofibrosarcoma protuberans of the vulva. Obstet Gynecol Int 2009;2009:547-672.
18. Edelweiss M, Malpica A. Dermatofibrosarcoma protuberans of the vulva: a clinicopathologic and immunohistochemical study of 13 cases. Am J Surg Pathol 2010;34:393-400.
19. Young C, Albertini M. Atrophic dermatofibrosarcoma protuberans: case report, review, and proposed molecular mechanisms. J Am Acad Dermatol 2003;49:761-4. (Pubitemid 37210305)
20. Fujimoto M, Kikuchi K, Okochi H, Furue M. Atrophic dermatofibrosarcoma protuberans: a case report and review of the literature. Dermatology 1998;196:422-4.
21. Page E, Assaad D. Atrophic dermatofibroma and dermatofibrosarcoma protuberans. J Am Acad Dermatol 1987;17:947-50. (Pubitemid 18021882)
22. Llombart B, Sanmartin O, Lopez-Guerrero J, Monteagudo C. et al. Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB) study with therapeutic implications. Histopathology 2009;54:860-72.
23. Mentzel, T . Sarcomas of the skin in the elderly. Clin Dermatol 2011;29:80-90.
24. Han W, Hu Q, Yang X, Wang Z. et al. Nodular fasciitis in the orofacial region. Int J Oral Maxillofac Surg 2006;35:924-7. (Pubitemid 44542557)
25. Gershtenson P, Krunic A, Chen H. Multiple clustered dermatofibroma: case report and review of the literature. J Cutan Pathol 2010;37:e42-5.
26. Silverman J, Tamsen A. CD34 and factor XIIIa-positive microvascular dendritic cells and the family of fibrohistiocytic mesenchymal tumors. Am J Dermatopathol 1998;20:533-6. (Pubitemid 28463428)
27. Aiba S, Tabata N, Ishii H, Ootani H, et al. Dermatofibrosarcoma protuberans is a unique fibrohistiocytic tumour expressing CD34. Br J Dermatol 1992;127:79-84.
28. Kutzner H. Expression of the human progenitor cell antigen CD34 (HPCA-1) distinguishes dermatofibrosarcoma protuberans from fibrous histiocytoma in formalin-fixed, paraffin-embedded tissue. J Am Acad Dermatol 1993;28:613-7. (Pubitemid 23104238)
29. Goldblum J, Tuthill R. CD34 and factor-XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma. Am J Dermatopathol 1997;19:147-53. (Pubitemid 27184728)
30. Abenoza P, Lillemoe T. CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans. Am J Dermatopathol 1993;15:429-34. (Pubitemid 23303044)
31. Lemm D, Mugge L, Mentzel T, Hoffken K. Current treatment option in dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol 2009;135:653-65.
32. Kim H, Lee J, Kim S, Seo Y, et al. Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34. Br J Dermatol 2007;157:319-24. (Pubitemid 47083868)
33. Cribier B, Nocacco G, Peltre B, Grosshans E. Stromelysin 3 expression: a useful marker for the differential diagnosis dermatofibroma versus dermatofibrosarcoma protuberans. J Am Acad Dermatol 2002;46:408-13. (Pubitemid 34225406)
34. West R, Harvell J, Linn S, Liu C, et al. Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberans. Am J Surg Pathol 2004;28:1063-9. (Pubitemid 38971432)
35. Lisovsky M, Hoang M, Dresser K. Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans. Mod Pathol 2008;21:31-8.
36. Bednar B. Storiform neurofibromas of the skin, pigmented and nonpigmented. Cancer 1957;10:368-76.
37. Frierson H, Cooper P. Myxoid variant of dermatofibrosarcoma protuberans. Am J Surg Pathol 1983;7:445-50. (Pubitemid 13006790)
38. Mentzel T, Scharer L, Kazakov D, Michal M. Myxoid Dermatofibrosarcoma protuberans: clinicopathologic, immunohistochemical, and molecular analysis of eight cases. Am J Dermatopathol 2007;29:443-8. (Pubitemid 47463852)
39. Shmookler B, Enzinger F, Weiss S. Giant cell fibroblastoma: a juvenile form of dermatofibrosarcoma protuberans. Cancer 1989;64:2154-61. (Pubitemid 19280419)
40. Terrier-Lacombe M, Guillou L, Maire G, Terrier P, et al. Dermatofibrosarcoma protuberans, giant cell fibroblastoma, and hybrid lesions in children: clinicopathologic comparative analysis of 28 cases with molecular data - a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol 2003;27:27-39. (Pubitemid 36014896)
41. Zelger BW, Ofner D, Zelger BG. Atrophic variants of dermatofibroma and dermatofibrosarcoma protuberans. Histopathology 1995;26:519-27.
42. Abbott J, Oliveira A, Nascimento A. The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans. Am J Surg Pathol 2006;30:436-43. (Pubitemid 43740143)
43. Mentzel T, Beham A, Katenkamp D, Dei Tos A, et al. Fibrosarcomatous ('high-grade') dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol 1998;22:576-87. (Pubitemid 28213745)
44. Goldblum J, Reith J, Weiss S. Sarcomas arising in dermatofibrosarcoma protuberans. A reappraisal of biologic behaviour in eighteen cases treated by wide local excision with extended clinical follow up. Am J Pathol 2000;24:1125-30. (Pubitemid 30612834)
45. Ding J, Hashimoto H, Enjoji M. Dermatofibrosarcoma protuberans with fibrosarcomatous areas: a clinicopathologic study of nine cases and a comparison with allied tumors. Cancer 1989;64:721-9. (Pubitemid 19185226)
46. Naeem R, Lux M, Huang S, Naber S, et al. Ring chromosomes in dermatofibrosarcoma protuberans are composed of interspersed sequences from chromosomes 17 and 22. Am J Pathol 1995;147:1553-8.
47. Simon M, Pedeutour F, Sirvent N, Grosgeorge J, et al. Deregulation of the platelet derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet 1997;15:95-8. (Pubitemid 27014958)
48. Sandberg A, Bridge J. Updates on the cytogenetics and molecular genetics of bone and soft-tissue tumors: dermatofibrosarcoma protuberans and giant cell fibroblastoma. Cancer Genet Cytogenet 2003;140:1-12. (Pubitemid 36110633)
49. Shimuzu A, O'Brien K, Sjoblum T, Pietras K, et al. The dermatofibrosarcoma protuberans-associated collagen type I alpha1/platelet- derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res 1999;59:3719-23. (Pubitemid 29381878)
50. Gisselsson D, Hoglund M, O'Brien K, Dumanski J, et al. A case of dermatofibrosarcoma protuberans with a ring chromosome 5 and a rearranged chromosome 22 containing amplified COL1A1 and PDGFB sequences. Cancer Lett 1998;133:129-34. (Pubitemid 29069036)
51. Sonobe H, Furihata M, Iwata J, Ohtsuki Y, et al. Dermatofibrosarcoma protuberans harboring t(9;22)(q32; q12.2). Cancer Genet Cytogenet 1999;110:14-8. (Pubitemid 29157803)
52. Patel K, Szabo S, Hernandez V, Prieto V, et al. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Hum Pathol 2008;39:184-93.
53. Domanski H, Gustafson P. Cytologic features of primary, recurrent, and metastatic dermatofibrosarcoma protuberans. Cancer 2002;96:351-61. (Pubitemid 37356010)
54. Torreggiani W, Al-Ismail K, Munk P, Nicolaou S, et al. Dermatofibrosarcoma protuberans: MR imaging features. AJR Am J Roentgenol 2002;178:989-93. (Pubitemid 34250244)
55. Thornton S, Reid J, Papay F, Vidimos A. Childhood dermatofibrosarcoma protuberans: role of preoperative imaging. J Am Acad Dermatol 2005;53:76-83. (Pubitemid 40826698)
56. Lee S, Mahoney M, Shaughnessy E. Dermatofibrosarcoma protuberans of the breast: imaging features and review of the literature. Am J Roentgenol 2009;193:W64-9.
57. Mavili M, Gursu K, Gokoz A. Dermatofibrosarcoma with lymph node involvement. Ann Plast Surg 1994;32:438-40. (Pubitemid 24117954)
58. Rutgers E, Kroon B, Albus-Luttner C, Gortzak E. Dermatofibrosarcoma protuberans: treatment and prognosis. Eur J Surg Oncol 1992;18:241-8.
59. Enneking W, Spanier S, Goodman M. Current concepts review. The surgical staging of musculoskeletal sarcoma. J Bone Joint Surg Am 1980;62:1027.
60. Edge S, Byrd D, Compton C, Fritz A, et al. editors. American Joint Committee on Cancer Cancer Staging Manual, 7th ed. New York: Springer, 2010.
61. Burkhardt B, Soule E, Winkelmann R, Ivins J. Dermatofibrosarcoma protuberans. Study of fifty-six cases. Am J Surg 1966;111:638-44.
62. Roses D, Valensi Q, LaTrenta G, Harris M. Surgical treatment of dermatofibrosarcoma protuberans. Surg Gynecol Obstet 1986;162:449-52. (Pubitemid 16026861)
63. Chattopadhyay T, Singh M, Arunabh . Dermatofibrosarcoma protuberans: a clinicopathological study of ten cases. Jpn J Surg 1986;16:435-8. (Pubitemid 17009230)
64. National Comprehensive Cancer Network (NCCN) guidelines [on-line]. Available from: www.nccn.org (accessed on January 7, 2012).
65. Farma J, Ammori J, Zager J, Marzban S, et al. Dermatofibrosarcoma protuberans: how far should we resect? Ann Surg Oncol 2010;17:2112-8.
66. Barnes L, Coleman J, Johnson J. Dermatofibrosarcoma protuberans of the head and neck. Arch Otolaryngol 1984;111:132-8.
67. Brabant B, Revol M, Vergote T, Servant J, et al. Dermatofibrosarcoma protuberans of the chest and the shoulder: wide and deep excisions with immediate reconstruction. Plast Reconstr Surg 1993;92:459-62. (Pubitemid 23230637)
68. Arnaud E, Perrault M, Revol M, Servant J, et al. Surgical treatment of dermatofibrosarcoma protuberans. Plast Reconstr Surg 1997;100:884-95. (Pubitemid 27386229)
69. Stojadinovic A, Karpoff H, Antonescu C, Shah J, et al. Dermatofibrosarcoma protuberans of the head and neck. Ann Surg Oncol 2000;7:696-704.
70. Stojadinovic A, Hoos A, Karpo H, Leung D, et al. Soft tissue tumors of the abdominal wall. Analysis of disease patterns and treatment. Arch Surg 2001;136:70-9. (Pubitemid 32064124)
71. Khatri V, Galante J, Bold R, Schneider P, et al. Dermatofibrosarcoma protuberans: reappraisal of wide local excision and impact of inadequate initial treatment. Ann Surg Oncol 2003;10:1118-22. (Pubitemid 40486838)
72. Chang C, Jacobs I, Salti G. Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol 2004;30:341-5. (Pubitemid 38425655)
73. DuBay D, Cimmino V, Lowe L. Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer 2004;100:1008-16. (Pubitemid 38222862)
74. Behbahani R, Patenotre P, Capon N, Martinot-Duquennoy V, et al. Vers une réduction des marges latérales dans les dermatofibrosarcomes de Darier et Ferrand? Étude rétrospective de 34 cas. Ann Chir Plast Esthet 2005;50:179-85. (Pubitemid 40826572)
75. Monnier D, Vidal C, Martin L, Danzon A, et al. Dermatofibrosarcoma protuberans: a population-based cancer registry descriptive study of 66 consecutive cases diagnosed between 1982 and 2002. J Eur Acad Dermatol Venereol 2006;20:1237-42. (Pubitemid 44614621)
76. Popov, Bohling T, Asko-Seljavaara S, Tukiainen E. Microscopic margins and results of surgery for dermatofibrosarcoma protuberans. Plast Reconstr Surg 2007;119:1779-84. (Pubitemid 46632061)
77. Paradisi A, Abeni D, Rusciani A, Cigna E, et al. Dermatofibrosarcoma protuberans: wide local excision vs. Mohs micrographic surgery. Cancer Treat Rev 2008;34:728-36.
78. Yu W, Tsoukas M, Chapman S, Rosen J. Surgical treatment for dermatofibrosarcoma protuberans: the Dartmouth experience and literature review. Ann Plast Surg 2008;60:288-93.
79. Heuvel S, Suurmeijer A, Pras E, Van Ginkel R, et al. Dermatofibrosarcoma protuberans: recurrence is related to the adequacy of surgical margins. Eur J Surg Oncol 2009;36:89-94.
80. Meguerditchian A, Wang J, Lema B, Kraybill W, et al. Wide excision or Mohs micrographic surgery for the treatment of primary dermatofibrosarcoma protuberans. Am J Clin Oncol 2010;33:300-3.
81. Fields R, Hameed M, Qin L. Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy. Ann Surg Oncol 2011;18:328-36.
82. Ratner D, Thomas C, Johnson T, Sondak V, et al. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol 1997;37:600-13. (Pubitemid 27446732)
83. Parker T, Zitelli J. Surgical margins for the excision of dermatofibrosarcoma protuberans. J Am Acad Dermatol 1995;32:233-6.
84. Gloster H Jr, Harris K, Roenigk R. A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of dermatofibrosarcoma protuberans. J Am Acad Dermatol 1996;35:82-7. (Pubitemid 26231329)
85. Garcia C, Viehman G, Hitchcock M, Clark R. Dermatofibrosarcoma protuberans treated with Mohs surgery. A case with CD34 immunostaining variability. Dermatol Surg 1996;22:177-9. (Pubitemid 26069624)
86. Dawes K, Hanke C. Dermatofibrosarcoma protuberans treated with Mohs micrographic surgery: cure rates and surgical margins. Dermatol Surg 1996;22:530-4. (Pubitemid 26200108)
87. Haycox C, Odland P, Olbricht S, Casey B. Dermatofibrosarcoma protuberans (DFSP): growth characteristics based on tumor modeling and a review of cases treatedwith Mohs micrographic surgery. Ann Plast Surg 1997;38:246-51. (Pubitemid 27137176)
88. Hafner J, Schutz K, Morgenthaler W, Steiger E, et al. Micrographic surgery ('slow Mohs') in cutaneous sarcomas. Dermatology 1999;198:37-43. (Pubitemid 29086333)
89. Huether M, Zitelli J, Brodland D. Mohs micrographic surgery for the treatment of spindle cell tumors of the skin. J Am Acad Dermatol 2001;44:656-9. (Pubitemid 32249525)
90. Ah-Weng A, Marsden J, Sanders D, Waters R. Dermatofibrosarcoma protuberans treated by micrographic surgery. Br J Cancer 2002;87:1386-9. (Pubitemid 36044312)
91. Nouri K, Rashmi L, Jimenez G, Robins P. Mohs micrographic surgery for dermatofibrosarcoma protuberans: University of Miami and NYU experience. Dermatol Surg 2002;28:1060-4. (Pubitemid 35424808)
92. Tom W, Hybarger C, Rasgon B. Dermatofibrosarcoma protuberans of the head and neck: treatment with Mohs surgery using inverted horizontal paraffin sections. Laryngoscope 2003;113:1289-93. (Pubitemid 36944667)
93. Wacker J, Khan-Durani B, Hartschuh W. Modified Mohs micrographic surgery in the therapy of dermatofibrosarcoma protuberans: analysis of 22 patients. Ann Surg Oncol 2003;11:438-44.
94. Snow S, Gordon E, Larson P, Bagheri M, et al. Dermatofibrosarcoma protuberans: a report of 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature. Cancer 2004;101:28-38. (Pubitemid 38812420)
95. Chacon M, Gonzalez A, Urrutia G, et al. Dermatofibrosarcoma protuberans (DFSP): Mohs surgery technique and prognostic factors. J Clin Oncol 2004 ASCO annual meeting proceedings (post-meeting edition). Vol 22 14S (July 15 Supplement) 2004:9066.
96. Thomas C, Wood G, Marks V. Mohs micrographic surgery in the treatment of rare aggressive cutaneous tumors: the Geisinger experience. Dermatol Surg 2007;33:333-9. (Pubitemid 46328233)
97. Roh M, Bae B, Chung K. Mohs' micrographic surgery of dermatofibrosarcoma protuberans. Clin Exp Dermatol 2010;35:849-52.
98. Tan W, Barlow R, Robson A, Kurwa H, et al. Dermatofibrosarcoma protuberans: 35 patients treated with Mohs micrographic surgery using paraffin sections. Br J Dermatol 2011;164:363-4.
99. Massey R, Tok J, Strippoli B, Szabolocs M, et al. A comparison of frozen and paraffin sections in dermatofibrosarcoma protuberans. Dermatol Surg 1998;24:995-8. (Pubitemid 28453048)
100. Jimenez F, Grichnik J, Buchanan M, Clark R. Immunohistochemical margin control applied to Mohs micrographic surgical excision of dermatofibrosarcoma protuberans. J Dermatol Surg Oncol 1994;20:687-9. (Pubitemid 24322506)
101. Sjoblom T, Shimizu A, O'Brien KP, Pietras K, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001;61:5778-83. (Pubitemid 32769094)
102. Maki R, Awan R, Dixon R, Jhanwar S, et al. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002;100:623-6. (Pubitemid 34832970)
103. Rubin B, Schuetze S, Eary J, Norwood T, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002;20:3586-91. (Pubitemid 34983217)
104. Mizutani K, Tamada Y, Hara K, Tsuzuki T, et al. Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans. Br J Dermatol 2004;151:235-7. (Pubitemid 39061309)
105. Labropoulos S, Fletcher J, Oliveira A, Papadopoulos S, et al. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anticancer Drugs 2005;16:461-6. (Pubitemid 40434613)
106. McArthur G, Demetri G, van Oosterom A, Heinrich M, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005;23:866-73. (Pubitemid 46224187)
107. Price V, Fletcher J, Zielenska M, Cole W, et al. Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans. Pediatr Blood Cancer 2005;44:511-5. (Pubitemid 40614501)
108. Kasper B, Lossignol D, Gil T, Flamen P, et al. Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp. Anticancer Drugs 2006;17:1223-5. (Pubitemid 44673404)
109. Savoia P, Ortoncelli M, Quaglino P, Bernengo M. Imatinib mesylate in the treatment of a large unresectable dermatofibrosarcoma protuberans: a case study. Dermatol Surg 2006;32:1097-102. (Pubitemid 44197467)
110. Mehrany K, Swanson N, Heinrich M, Weenig R, et al. Dermatofibrosarcoma protuberans: a partial response to imatinib therapy. Dermatol Surg 2006;32:456-9.
111. Wright T, Petersen J. Treatment of recurrent dermatofibrosarcoma protuberans with imatinib mesylate, followed by Mohs micrographic surgery. Dermatol Surg 2007;33:741-4. (Pubitemid 46855056)
112. Lemm D, Muegge L, Hoffken K, Aklan T, et al. Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans - a case report. Oral Maxillofac Surg 2008;12:209-13.
113. Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 2010;28:1772-9.
114. Kérob D, Porcher R, Vérola O, Dalle S, et al. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. Clin Cancer Res 2010;16:3288-95.
115. Rutkowski P, Dȩbiec-Rychter M, Nowecki Z, Michej W, et al. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection. J Eur Acad Dermatol Venereol 2011;25:264-70.
116. Full prescribing information for imatinib [on-line]. Available from: http://www.gleevec.com/patient/gleevec-cml.jsp (accessed January 8, 2012).
117. Marks L, Suit H, Rosenberg A, Wood W. Dermatofibrosarcoma protuberans treated with radiation therapy. Int J Radiat Oncol Biol Phys 1989;17:379-84. (Pubitemid 19203087)
118. Haas R, Keus R, Loftus B, Rutgers E, et al. The role of radiotherapy in the local management of dermatofibrosarcoma protuberans. Eur J Cancer 1997;33:1055-60. (Pubitemid 27310781)
119. Sun L, Wang C, Huang C, Leung S, et al. Dermatofibrosarcoma protuberans: treatment results of 35 cases. Radiother Oncol 2000;57:175-81.